Filtered By:
Source: LANCET
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 186 results found since Jan 2013.
Articles Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study
Single intracerebral doses of CTX-DP up to 20 million cells induced no adverse events and were associated with improved neurological function. Our observations support further investigation of CTX-DP in stroke patients.
Source: LANCET - August 2, 2016 Category: Journals (General) Authors: Dheeraj Kalladka, John Sinden, Kenneth Pollock, Caroline Haig, John McLean, Wilma Smith, Alex McConnachie, Celestine Santosh, Philip M Bath, Laurence Dunn, Keith W Muir Tags: Articles Source Type: research
Obituary Philip Majerus
Physician and biochemist who showed small doses of aspirin reduce the risk of heart attack and stroke. Born on July 10, 1936, in Chicago, IL, USA, he died with prostate cancer on June 8, 2016, in University City, MO, USA, aged 79 years.
Source: LANCET - July 29, 2016 Category: Journals (General) Authors: Alison Snyder Tags: Obituary Source Type: research
Comment Stroke is largely preventable across the globe: where to next?
Despite the ever-increasing disease burden of stroke in the world,1 accurate data on stroke risk factors are still scarce. In the first phase of the INTERSTROKE study,2 more than 90% of strokes (ischaemic stroke and intracerebral haemorrhage) were attributed to just ten risk factors. However, the study was restricted to developing countries only, and was not powered to explore age, sex, ethnicity, and regional variations in the effect of risk factors or pathological type of stroke, such as ischaemic stroke and intracerebral haemorrhage.
Source: LANCET - July 14, 2016 Category: Journals (General) Authors: Valery L Feigin, Rita Krishnamurthi Tags: Comment Source Type: research
Articles Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study
Ten potentially modifiable risk factors are collectively associated with about 90% of the PAR of stroke in each major region of the world, among ethnic groups, in men and women, and in all ages. However, we found important regional variations in the relative importance of most individual risk factors for stroke, which could contribute to worldwide variations in frequency and case-mix of stroke. Our findings support developing both global and region-specific programmes to prevent stroke.
Source: LANCET - July 14, 2016 Category: Journals (General) Authors: Martin J O'Donnell, Siu Lim Chin, Sumathy Rangarajan, Denis Xavier, Lisheng Liu, Hongye Zhang, Purnima Rao-Melacini, Xiaohe Zhang, Prem Pais, Steven Agapay, Patricio Lopez-Jaramillo, Albertino Damasceno, Peter Langhorne, Matthew J McQueen, Annika Rosengre Tags: Articles Source Type: research
Comment The benefits of aspirin in early secondary stroke prevention
Aspirin is considered an affordable and widely available, if only modestly effective, thromboprophylactic for secondary stroke prevention. The two large randomised controlled trials of aspirin in acute ischaemic stroke reported that aspirin reduced the odds of early recurrent stroke at 2 –4 weeks by about 12% (odds ratio [OR] 0·88, 95% CI 0·79–0·97) and the odds of death or dependency at the end of follow-up by about 5% (OR 0·95, 0·91–0·99).1 The ten trials of aspirin for long-term secondary prevention in patients with previous transient ischaemic attack (TIA) or ischaem ic stroke reported that aspirin reduced ...
Source: LANCET - May 17, 2016 Category: Journals (General) Authors: Graeme J Hankey Tags: Comment Source Type: research
Articles Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials
Our findings confirm that medical treatment substantially reduces the risk of early recurrent stroke after TIA and minor stroke and identify aspirin as the key intervention. The considerable early benefit from aspirin warrants public education about self-administration after possible TIA. The previously unrecognised effect of aspirin on severity of early recurrent stroke, the diminishing benefit with longer-term use, and the contrasting time course of effects of dipyridamole have implications for understanding mechanisms of action.
Source: LANCET - May 17, 2016 Category: Journals (General) Authors: Peter M Rothwell, Ale Algra, Zhengming Chen, Hans-Christoph Diener, Bo Norrving, Ziyah Mehta Tags: Articles Source Type: research
Department of Error Department of Error
Bray BD, Cloud GC, James MA, et al. Weekly variation in health-care quality by day and time of admission: a nationwide, registry-based, prospective cohort study of acute stroke care. Lancet 2016; 388: 170–77. In this Article, in the findings section of the Summary and in the third paragraph of the Results, “sleep and language therapist” should have been “speech and language therapist”. This change has been made to the online version as of May 17, 2016, and the printed Article is correct.
Source: LANCET - May 16, 2016 Category: Journals (General) Tags: Department of Error Source Type: research
Articles Weekly variation in health-care quality by day and time of admission: a nationwide, registry-based, prospective cohort study of acute stroke care
The weekend effect is a simplification, and just one of several patterns of weekly variation occurring in the quality of stroke care. Weekly variation should be further investigated in other health-care settings, and quality improvement should focus on reducing temporal variation in quality and not only the weekend effect.
Source: LANCET - May 9, 2016 Category: Journals (General) Authors: Benjamin D Bray, Geoffrey C Cloud, Martin A James, Harry Hemingway, Lizz Paley, Kevin Stewart, Pippa J Tyrrell, Charles D A Wolfe, Anthony G Rudd, SSNAP collaboration Tags: Articles Source Type: research
Comment Platelets after intracerebral haemorrhage: more is not better
Spontaneous intracerebral haemorrhage has a disproportionally high burden of mortality and disability compared with other subtypes of stroke.1,2 As a clinician, when faced with a condition as devastating as intracerebral haemorrhage, one feels compelled to use any and all therapies available, even though at times evidence of effectiveness of those therapies is not yet established.1 This is particularly the case for many health-care providers on the front lines of emergency diagnosis and treatment for patients who have had an intracerebral haemorrhage while taking antiplatelet therapy.
Source: LANCET - May 9, 2016 Category: Journals (General) Authors: Calin I Prodan Tags: Comment Source Type: research
Articles Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial
Platelet transfusion seems inferior to standard care for people taking antiplatelet therapy before intracerebral haemorrhage. Platelet transfusion cannot be recommended for this indication in clinical practice.
Source: LANCET - May 9, 2016 Category: Journals (General) Authors: M Irem Baharoglu, Charlotte Cordonnier, Rustam Al-Shahi Salman, Koen de Gans, Maria M Koopman, Anneke Brand, Charles B Majoie, Ludo F Beenen, Henk A Marquering, Marinus Vermeulen, Paul J Nederkoorn, Rob J de Haan, Yvo B Roos, PATCH Investigators Tags: Articles Source Type: research
Correspondence IST-3 stroke trial data available
The third International Stroke Trial1 was the largest ever randomised controlled trial of intravenous thrombolysis treatment for patients with acute ischaemic stroke. In accordance with our published protocol and statistical analysis plan, we made the patient data available for an individual patient data meta-analysis.2 We now wish to announce that the IST-3 collaborative group has lodged an anonymised version of the dataset with University of Edinburgh DataShare,3 to enable bona fide researchers to obtain access to the data.
Source: LANCET - May 6, 2016 Category: Journals (General) Authors: Peter Sandercock, Joanna Wardlaw, Richard Lindley, William Whiteley, Geoff Cohen Tags: Correspondence Source Type: research
Obituary Andrew Herxheimer
Clinical pharmacologist who founded Drug and Therapeutics Bulletin. Born in Berlin, Germany, on Nov 4, 1925, he died after a stroke in London, UK, on Feb 21, 2016, aged 90 years.
Source: LANCET - April 15, 2016 Category: Journals (General) Authors: Geoff Watts Tags: Obituary Source Type: research
Comment Can biomarkers balance stroke and bleeding risk?
Age and previous stroke, together with other clinical risk factors (often summarised in the CHA2DS2VASc score), identify patients with atrial fibrillation at high risk for stroke. Dose-adjusted warfarin prevents ischaemic strokes, prolongs life, and maintains autonomy in such patients.1,2 Hence, oral anticoagulation is currently recommended for all patients with atrial fibrillation with two of the CHA2DS2VASc risk factors, and should be considered in those with one of them.1,2 Although even reinitiation of anticoagulation after an intracerebral bleed seems to be associated with improved outcomes,3,4 bleeding is a major rea...
Source: LANCET - April 3, 2016 Category: Journals (General) Authors: Paulus Kirchhof, Larissa Fabritz Tags: Comment Source Type: research
Obituary John Kurtzke
Pioneering neuroepidemiologist who studied multiple sclerosis. Born on Sept 14, 1926, in Brooklyn, NY, USA, he died from a stroke on Dec 1, 2015, in Falls Church, VA, USA, aged 89 years.
Source: LANCET - April 1, 2016 Category: Journals (General) Authors: Alison Snyder Tags: Obituary Source Type: research
Department of Error Department of Error
Howard G, Roubin GS, Jansen O, et al, on behalf of the Carotid Stenting Trialists' Collaboration. Association between age and risk of stroke or death from carotid endarterectomy and carotid stenting: a meta-analysis of pooled patient data from four randomised trials. Lancet 2016; 387: 1305–11—In the abstract of this Article, the first sentence of the interpretation section should read “In these RCTs, CEA was clearly superior to CAS in patients aged 70–74 years and older”. This correction has been made to the online version as of March 1, 2016.
Source: LANCET - February 29, 2016 Category: Journals (General) Tags: Department of Error Source Type: research
